You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Optimizing Vaccines by Targeting Dendritic Cells with IFNa and IFNb Inducing Adjuvants

    SBC: PARABON NANOLABS INC            Topic: NIAID

    DESCRIPTION provided by applicant There is a critical need for a safe and effective vaccine against HIV Decades of work have been invested in understanding the immune response to infection and different approaches have been taken to develop vaccines that are effective in preventing and treating the disease While effective in animal models none have been as effective in humans The immune ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Development of Optimized Endectocide-treated Bird Feed Formulations for West Nile Virus Control

    SBC: TDA Research, Inc.            Topic: NIAID

    Project Summary Abstract Development of Optimized Endectocide treated Bird Feed Formulations for West Nile Virus Control STTR Phase I Application PIs Brady Clapsaddle TDA Research Inc Dr Brian Foy Colorado State University West Nile Virus WNV is the leading cause of domestically acquired arboviral disease in the United States resulting in significant disease and death every year in both ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. OXAID: Oxygenating Hydrogel for Diabetic Wound Care

    SBC: O2 RegenTech LLC            Topic: 200

    DESCRIPTION provided by applicant Oxygen plays a significant role in wound healing and maintaining elevated tissue oxygenation levels are an important factor in the dermal healing response Specifically non healing diabetic chronic wounds defined as lasting andgt weeks often show devastatingly low oxygen concentrations as low as mmHg oxygen partial pressure In the USA there are more ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers

    SBC: NAJIT TECHNOLOGIES INC            Topic: NIAID

    DESCRIPTION provided by applicant Peptide conjugated phosphorodiamidate morpholino oligomers PPMO are single stranded nucleic acid analogs able to modulate gene expression through steric blocking of complementary RNA PPMO are composed of two components an antisense morpholino oligomer cargo covalently conjugated to a cell penetrating delivery peptide PPMO are completely nuclease resistant ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Automated Head Turn Tracking and Other Innovations for VRA

    SBC: INTELLIGENT HEARING SYSTEMS CORP            Topic: NIDCD

    DESCRIPTION (provided by applicant): The overall goal of this study is to develop a head tracking procedure for the automated assessment of hearing in infants using Visual Reinforcement Audiometry (VRA). The head tracking procedure will be incorporated into the Intelligent Visual Reinforcement Audiometry (IVRA) system from Intelligent Hearing Systems Corp. The IVRA system currently provides automa ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Direct-read monitor for airborne viral pathogens

    SBC: AEROSOL DEVICES INC            Topic: NIAID

    Aerosolized pathogenssuch as Influenza virusescan spread rapidly and silently throughout a populationcausing severe outbreaks that can be difficult to controlEarly detection of these airborne pathogens is key to controlling outbreaksespecially among vulnerable populations such as in hospitalstreatment centers or nursing homesYet available methods are neither rapidnor portableCurrent methods rely h ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Survey and Test Platform for Use in Underserved Populations

    SBC: ADVANCED MEDICAL ELECTRONICS CORP            Topic: NEI

    DESCRIPTION (provided by applicant): Advanced Medical Electronics Corp, in collaboration with the Johns Hopkins University School of Medicine, proposes to develop a hardware/software platform suitable for administering a variety of tests and survey instruments to underserved populations in settings that can range from living rooms to libraries, community centers to nursing homes, and from inner ci ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Body Worn EMG Controlling of Assistive Robotic Arm for Stroke Rehabilitation

    SBC: ADVANCED MEDICAL ELECTRONICS CORP            Topic: NINDS

    DESCRIPTION (provided by applicant): Stroke is the leading cause of adult disability and the third leading cause of death in the United States. Approximately 15 million people in the world, and more than 700,000 people in the United States, experience a stroke each year. Following a hemispheric stroke, motor control of extremities on one side of the body is usually affected. Many patients suffer a ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Monitored Breathing Awareness Therapy for Insomnia Disorder in Older Adults

    SBC: ADVANCED MEDICAL ELECTRONICS CORP            Topic: NIA

    DESCRIPTION provided by applicant Insomnia of sufficient clinical severity to meet diagnostic criteria is present in approximately of older adults nearly million individuals n the US alone If left untreated it can lead to increased rates of depression cognitive impairment and cardiovascular disease Treatment relies on pharmacotherapy such as sedative hypnotic therapy which is ass ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Development of DRα1-MOG-35-55 for treatment of DR2 negative MS subjects

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: NIAID

    DESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government